1334296-12-6

Seribantumab (0.6-1 mg; i.p. twice weekly for once) reduces tumor growth in non-small cell lung cancer (NSCLC) patient-derived xenograft (PDX) mice model with a higher efficacy than afatinib, blocks phosphorylation of growth modulators and induces expression of apoptosis markers in vivo^[1]. Seribantumab (1-10 mg; i.p. twice weekly for once) eliminates the vast majority of tumor cells and causes no significant change in overall animal health or weight in High-grade serous ovarian cancer (HGSOC) mice model^[1].